CC
OVID icon

Cannell Capital’s Ovid Therapeutics OVID Stock Holding History

Cannell Capital’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-22,620
Closed -$58.4K – 79
2023
Q1 		$58.4K Hold
22,620
– – 0.01% 68
2022
Q4 		$42.1K Hold
22,620
– – 0.01% 72
2022
Q3 		$42K Buy
22,620
+16,671
+280% +$34.9K 0.01% 73
2022
Q2 		$13K Buy
+5,949
New +$14.4K ﹤0.01% 68

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cannell Capital's OVID Position: Q2 2023 in Review

Cannell Capital sold out of Ovid Therapeutics (OVID) in Q2 2023, closing a stake of 22,620 shares — an estimated $58.4K sold.

Cannell Capital first reported a position in OVID in Q2 2022 and held it in 4 quarters. The position peaked at $58.4K in Q1 2023. 69 funds tracked by Wall St. Rank hold OVID as of Q2 2023.

  • Cannell Capital reported no remaining Ovid Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Cannell Capital sold 22,620 Ovid Therapeutics shares in Q2 2023, an estimated $58.4K.
  • Cannell Capital first reported a position in Ovid Therapeutics in Q2 2022 and held it in 4 quarters.
  • Cannell Capital's Ovid Therapeutics position peaked at $58.4K in Q1 2023.
  • 69 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2023.

Based on Cannell Capital's 13F filing for Q2 2023, filed 14 Aug 2023.